Benjamin Leach, M.D.
- Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
- Medical Oncologist
Benjamin Leach, M.D.
- Medical Oncology
Areas of Expertise
Other Languages Spoken
My own approach to patient care is mirrored by the culture at City of Hope – the cornerstone being compassion, innovation and collaboration.”
Benjamin Leach, M.D., takes a passionate approach to cancer treatment incorporating leading-edge therapies from precision medicine to immunotherapy, with a relentless commitment to serving his patients and improving their quality of life.
“It’s a privilege to be welcomed into patients’ lives,” he says.
Dr. Leach received his medical degree at Tulane University in New Orleans, completed his internship and residency at Los Angeles County + USC Medical Center and continued his training with a hematology/oncology fellowship at New York-Presbyterian Hospital/Weill Cornell Medical College. At Weill Cornell, he pursued his interest in targeted treatment, studying the WNT signaling pathway implicated in colorectal cancer development, for which he was awarded the Weill Department of Medicine Fellows Award in Research.
Dr. Leach is excited to be returning to Southern California; he’ll treat patients at City of Hope’s Mission Hills facility.
- 2017-present, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Mission Hills, CA
- 2011, Doctor of Medicine, Tulane University, New Orleans, Louisiana
- 2005, Bachelor of Science, Biological Sciences, University of Illinois, Chicago, Illinois
- 2014-2017, Hematology and Oncology, New York-Presbyterian Hospital, Weill Cornell Medical College, New York, New York
- 2011-2014, Intern and Resident, Department of Medicine, Los Angeles County + USC Medical Center, Los Angeles, California
- O’Rourke KP, Loizou E, Livshits G, Schatoff EM, Baslan T, Manchado E, Simon J, Leach BI, Han T, Pauli C, Beltran H, Rubin MA, Dow LE, Lowe SW. Rapid generation of colorectal cancer by engineered organoid transplantation. Nature Biotechnology. In Press. March 2017.
- Leach BI, Galletti G, Lam L, Tagawa, ST. Mechanisms of resistance to systemic therapy in metastatic castration resistant prostate cancer. Submitted for review. March 2017.
- Schatoff EM, Leach BI, Dow LE. WNT Signaling and Colorectal Cancer. Curr Colorectal Cancer Rep. Advance online publication. Feb 2017.
- Fedashchin A, Cernota WH, Gonzalez MC, Leach BI, Kwan N, Wesley RK, Weber JM. Random transposon mutagenesis of the Saccharopolyspora erythraea genome reveals additional genes influencing erythromycin biosynthesis. FEMS Microbiol Lett. 2015 Nov; 362(22)
- Leach BI, Sun B, Petrovic L, Liu SV. Breast metastasis from nasopharyngeal carcinoma: A case report and review of the literature. Oncology Letters. 2013 June; 5 (6): 1859-61.
- Weber JM, Cernota WH, Gonzalez MC, Leach BI, Reeves AR, Wesley RK. An erythromycin process improvement using the diethyl methylmalonate-responsive (Dmr) phenotype of the Saccharopolyspora erythraea mutB strain. Appl Microbiol Biotechnol. 2012 Feb; 93 (4): 1575-83.
- Reeves AR, Brikun IA, Cernota WH, Leach BI, Gonzalez MC, Weber JM. Engineering of the methylmalonyl-CoA metabolite node of Saccharopolyspora erythraea for increased erythromycin production. Metabolic Engineering. 2007 May; 9 (3): 293-303.
- Reeves AR, Brikun IA, Cernota WH, Leach BI, Gonzalez MC, Weber JM. Effects of methylmalonyl-CoA mutase gene knockouts on erythromycin production in carbohydrate-based and oil-based fermentations of Saccharopolyspora erythraea. J Ind Microbiol Biotechnol. 2006 Jul; 33 (7): 600-9.